Lymphoma & Leukaemia Research Review, Issue 6

In this issue:

Hyper-CVAD plus ponatinib or dasatinib in Ph+ ALL
Dasatinib and nilotinib for CML in chronic phase
Inferior PFS after SCT for double-expressor and double-hit lymphomas
Blinatumomab in paediatric ALL
Selinexor + fludarabine and cytarabine in paediatric ALL
MRD assessment improves outcome prediction in CLL
Mediastinal gray zone lymphoma
Survival differences in and outside clinical trials for HL
Ibrutinib in relapsed CLL after alloHCT
Rituximab, bendamustine, and low dose cytarabine for induction in elderly MCL

Please login below to download this issue (PDF)

Subscribe